Overview

Efficacy and Safety of Olaparib in Pretreated Patients With Measurable Colorectal Cancer, Stratified by Microsatellite Instability (MSI) Status

Status:
Completed

Trial end date:
2012-03-01

Target enrollment:

Participant gender:

Summary

This study is being carried out to see if the new drug, olaparib (AZD2281), can effectively and safely treat advanced large bowel cancer. The primary goal of this clinical trial is to determine whether olaparib will have a beneficial effect on the patient's cancer by causing a response and increasing the time it takes for the cancer to progress.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Olaparib